NCT06363253

Pilot Study of the Human Metagenome in Metabolic Diseases

Name: Clinical Trial NCT06363253
Creator: Sengkang General Hospital
Keywords: Obesity,Sarcopenia,Sarcopenic Obesity,Chronic Inflammation,Metabolic Syndrome, No specific intervention, other, clinical trial, Singapore

Understanding the Role of the Human Metagenome in Obesity, Metabolic Diseases, Chronic Inflammation, Sarcopenia and Sarcopenic Obesity - a Pilot Study

Sengkang General Hospital·ClinicalTrials.gov·otherRecruiting

View on ClinicalTrials.gov →

Study focus

Disease/Condition: Obesity,Sarcopenia,Sarcopenic Obesity,Chronic Inflammation,Metabolic Syndrome
Drug/Device/Intervention: No specific intervention
Study type: Observational
Intervention type: other

Sponsor & location

Primary sponsor: Sengkang General Hospital
Location: Singapore, Singapore

Timeline & enrollment

Phase: N/A
Start date: Aug 14, 2023
End date: Dec 31, 2027
Enrollment: 600 participants

Primary outcome

Metagenomic alterations,Metabolomic alterations

Summary

This is a cohort study to understand the role of the human metagenome, and associated metabolites, in health and in various diseased states, in particular obesity as well as sarcopenia.  Recruited participants will have their fecal, salivary, urine, serum, and in certain instances, mucosal samples taken, for metagenomic sequencing and metabolite testing.  We hope to uncover various differences and signatures in the metagenome and metabolome in various diseased states, with potential future therapeutic applications in personalised medicine.

ICD-10 classifications

Obesity, unspecifiedObesityOther metabolic disordersOther obesityOther specified metabolic disorders

Data source

Registry: ClinicalTrials.gov
Trial ID: NCT06363253
Type: Non-Device Trial

About this record

Access comprehensive clinical trial information for NCT06363253 through Pure Global AI's free database. This phase not specified trial is sponsored by Sengkang General Hospital and is currently Recruiting. The study focuses on Obesity,Sarcopenia,Sarcopenic Obesity,Chronic Inflammation,Metabolic Syndrome. Target enrollment is 600 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.